Healthcare Industry News: OMRIX Biopharmaceuticals
News Release - August 28, 2006
OMRIX Biopharmaceuticals Announces Appointment of Nanci Prado to General CounselNEW YORK--(HSMN NewsFeed)--Aug. 28, 2006--OMRIX Biopharmaceuticals, Inc. ("OMRIX" or "The Company") (NASDAQ: OMRI ), a commercial-stage biopharmaceutical company that develops and markets biosurgical and passive immunotherapy products, today announced the appointment of Nanci I Prado as Vice President and General Counsel. Ms. Prado will report to Robert Taub, President and Chief Executive Officer of OMRIX Biopharmaceuticals, and will oversee the Company's corporate, securities compliance, governance and general legal matters.
Prior to joining OMRIX, Ms. Prado was a partner in the Corporate Group of the New York office of Dorsey & Whitney LLP. Previously, she was an attorney in the Business and Technology Group in the New York office of Brobeck, Phleger & Harrison LLP. In these positions, Ms. Prado advised numerous public companies on a broad range of corporate governance, equity and debt financing, merger and acquisition and securities compliance issues. Ms. Prado was admitted to the New York Bar in 1995 and the California Bar in 2002.
"We are pleased that Nanci I Prado has joined OMRIX as Vice President and General Counsel. Her corporate legal experience will be invaluable as we continue our development and fulfill the reporting requirements required of a public company," said Robert Taub, President and Chief Executive Officer of OMRIX Biopharmaceuticals.
Ms. Prado received her J.D. degree from Stanford Law School.
About OMRIX Biopharmaceuticals, Inc.
OMRIX, a commercial-stage biopharmaceutical company, develops and markets innovative biosurgical and passive immunotherapy products, utilizing its proprietary protein purification technology and manufacturing know-how. As part of its business strategy, OMRIX commercializes certain of its biosurgical products through collaborations with companies whose marketing and sales expertise are a complement to OMRIX's own areas of specialty. OMRIX's novel and easy-to-use biological-device convergence products address unmet medical needs. For more information, please visit: www.omrix.com.
Safe Harbor Statement
This press release contains forward-looking statements. Forward-looking statements provide the company's current expectations or forecasts of future events. Forward-looking statements include statements about the Company's expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. The company's actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the sections entitled "Risk factors" and "Management's discussion and analysis of financial condition and results of operations" in the company's Prospectus as filed with the Securities and Exchange Commission on April 21, 2006. Unless required by law, the company undertakes no obligation to publicly update or revise any forward-looking statement to reflect circumstances or events after the date of this press release.
Source: OMRIX Biopharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.